A carregar...
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
INTRODUCTION: Cancer immunotherapy represents one of the most important innovations in modern medicine. Durvalumab is an anti-programmed cell death ligand 1 (PDL-1) agent which is currently under investigation in several studies in combination with the anti-cytotoxic T lymphocyte-associated protein ...
Na minha lista:
| Publicado no: | Adv Ther |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Healthcare
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8279985/ https://ncbi.nlm.nih.gov/pubmed/34105088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-021-01796-6 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|